十一烷基肼 | 131645-01-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 十一烷基肼
• 英文名称: diazatridecan
• 英文别名: Undecyl-hydrazine；undecylhydrazine
• CAS: 131645-01-7
• 化学式: C₁₁H₂₆N₂
• 分子量: 186.341
• InChiKey: YHTQKJJDMAPMSS-UHFFFAOYSA-N

物化性质

• 沸点：
  238 °C(Press: 11 Torr)
• 密度：
  0.837±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  13
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  十一烷基肼 在 sodium azide 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 4-((1R,2S,3S)-3-azido-1,2-bis(benzyloxy)-4-(trityloxy)butyl)-1-undecyl-1H-pyrazole
  参考文献：
  名称：

  α-半乳糖苷神经酰胺鞘氨醇骨架中的杂芳族部分与 CD1d 的非共价相互作用

  摘要：

  合成了一系列在鞘氨醇骨架中含有杂环和芳香部分的 α-GalCer 类似物，通过与 CD1d 结合口袋上的三个芳香残基的非共价相互作用来提高 Th1/Th2 细胞因子谱的选择性。体外和体内生物学评估表明，α-GalCer 类似物 ( 6 ) 的处理诱导了自然杀伤 T 细胞的选择性刺激，以促进 Th2 细胞因子的分泌。

  DOI：

  10.1021/ml200278u
• 作为产物：
  描述：

  十一醛 在 甲酸 、 palladium on activated charcoal 、 氢气 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 9.0h， 生成 十一烷基肼
  参考文献：
  名称：

  α-半乳糖苷神经酰胺鞘氨醇骨架中的杂芳族部分与 CD1d 的非共价相互作用

  摘要：

  合成了一系列在鞘氨醇骨架中含有杂环和芳香部分的 α-GalCer 类似物，通过与 CD1d 结合口袋上的三个芳香残基的非共价相互作用来提高 Th1/Th2 细胞因子谱的选择性。体外和体内生物学评估表明，α-GalCer 类似物 ( 6 ) 的处理诱导了自然杀伤 T 细胞的选择性刺激，以促进 Th2 细胞因子的分泌。

  DOI：

  10.1021/ml200278u

文献信息

• 알파-갈락토실세라마이드 유사체, 이의 제조방법 및 이를 포함하는 면역조절 이상으로 인한 질환의 치료 또는 예방용 약학적 조성물
  申请人：Spark Biopharma, Inc (주)스파크바이오파마(120160160632) Corp. No ▼ 110111-5956482BRN ▼441-88-00285

  公开号：KR101969129B1

  公开（公告）日：2019-04-15

  본 발명은 알파-갈락토실세라마이드 유사체, 이의 제조방법 및 이를 포함하는 면역조절 이상으로 인한 질환의 치료 또는 예방용 약학적 조성물에 관한 것으로, 더욱 상세하게는 NKT 세포 내 Th1 또는 Th2 반응의 선택적인 활성화를 유도할 수 있어 면역조절 이상으로 인한 질환의 치료 또는 예방에 효과적인 알파-갈락토실세라마이드 유사체, 이의 제조방법 및 이를 포함하는 면역조절 이상으로 인한 질환의 치료 또는 예방용 약학적 조성물에 관한 것이다.

  本发明涉及一种α-半乳甘露糖鞘氨醇类似物，其制备方法以及包含在免疫调节异常引起的疾病的治疗或预防药学组合物中，更详细地说，可以诱导NKT细胞内Th1或Th2反应的选择性激活，从而对免疫调节异常引起的疾病的治疗或预防具有有效作用的α-半乳甘露糖鞘氨醇类似物，其制备方法以及包含在免疫调节异常引起的疾病的治疗或预防用药学组合物。
• Azetidine ring compounds and drugs comprising the same
  申请人：Habashita Hiromu

  公开号：US20070135402A1

  公开（公告）日：2007-06-14

  It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds of the formula (I): wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary hypertension, renal diseases, myocardial infarction, angina pectoris, arrhythmia, portal hypertension, varicosity and the like), arteriosclerosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, respiratory diseases (e.g. bronchial asthma, chronic obstructive pulmonary diseases and the like), nephropathy, diabetes, hyperlipemia and the like.

  本发明旨在提供具有EDG-5拮抗作用的化合物。由于具有EDG-5拮抗作用，式（I）中的化合物：其中每个符号如描述中所定义的，其盐，N-氧化物，溶剂化物或其前药，可用作预防和/或治疗EDG-5介导的疾病的药物，例如血管收缩引起的疾病（例如脑血管痉挛疾病，心血管痉挛疾病，冠状动脉痉挛疾病，高血压，肺动脉高压，肾脏疾病，心肌梗死，心绞痛，心律失常，门脉高压，静脉曲张等），动脉硬化，肺纤维化，肝纤维化，肾脏疾病（例如肾病，糖尿病，高脂血症等）和其他疾病。
• Nitrogen-containing heterocyclic compounds and medicinal use thereof
  申请人：Habashita Hiromu

  公开号：US20070167459A1

  公开（公告）日：2007-07-19

  The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)

  式(I)和(II)所代表的化合物、其盐、N-氧化物或溶剂合物、或其前药，以及包含它们的制药组合物具有CXCR4调节作用，它们对各种炎症性疾病、各种过敏性疾病、艾滋病毒感染、或再生治疗剂具有治疗和预防作用。(其中环A代表可能具有取代基的含氮杂环基团；环B代表可能具有取代基的同环基团或可能具有取代基的杂环基团；Y代表可能具有取代基的碳氢基团、可能具有取代基的杂环基团、可能被保护的氨基、可能被保护的羟基或可能被保护的巯基；T代表环A或可能被保护的氨基。)
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：HABASHITA Hiromu

  公开号：US20120156219A1

  公开（公告）日：2012-06-21

  The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)

  化合物(I)和(II)的化学式、其盐、N-氧化物或其溶剂化物，或其前药以及包含它们的制药组合物具有CXCR4调节作用，对各种炎症性疾病、各种过敏性疾病、人类免疫缺陷病毒感染的获得性免疫缺陷综合症，或再生治疗剂具有治疗和预防作用。(其中环A代表一个含氮杂环基团，可以有取代基；环B代表一个同环基团，可以有取代基或一个含氮杂环基团，可以有取代基；Y代表一个碳氢基团，可以有取代基，一个含氮杂环基团，可以有取代基，一个氨基可以被保护，一个羟基可以被保护或一个巯基可以被保护；T代表环A或一个氨基可以被保护。)
• AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1698375A1

  公开（公告）日：2006-09-06

  It is intended to provide compounds having EDG-5 antagonism. Because of having EDG-5 antagonism, compounds of the formula (I): wherein each symbol is as defined in the description; salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof are useful as preventive and/or therapeutic agent for EDG-5 mediated diseases, for example, diseases caused by blood vessel contraction (e.g. cerebrovascular spasms disease, cardiovascular spasms diseases, coronary artery spasms disease, hypertension, pulmonary hypertension, renal diseases, myocardial infarction, angina pectoris, arrhythmia, portal hypertension, varicosity and the like), arteriosclerosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, respiratory diseases (e.g. bronchial asthma, chronic obstructive pulmonary diseases and the like), nephropathy, diabetes, hyperlipemia and the like.

  目的是提供具有 EDG-5 拮抗作用的化合物。由于具有 EDG-5 拮抗作用，式 (I) 的化合物： 其中各符号如描述中所定义；其盐类、其 N-氧化物、其溶解物或其原药可作为 EDG-5 介导的疾病的预防和/或治疗剂，例如，由血管收缩引起的疾病（如脑血管痉挛疾病、心血管痉挛疾病、冠状动脉痉挛疾病、高血压、肺动脉高压、肾脏疾病、心肌梗塞、心绞痛、心律失常、门静脉高压、静脉曲张等）、动脉硬化、肺纤维化、肝纤维化、肾纤维化、呼吸系统疾病（如支气管哮喘、肺结核、肺癌等）、心肌梗塞、心绞痛、心律失常、门静脉高压、静脉曲张等）。如支气管哮喘、慢性阻塞性肺病等）、肾病、糖尿病、高脂血症等。